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Abciximab During
Percutaneous Coronary
Intervention for ST-Segment
Elevation Myocardial Infarction
Intracoronary, Intravenous, or Not at All?*
John A. Bittl, MD
Ocala, Florida
The intravenous (IV) route is the standard way to admin-
ister abciximab to patients during percutaneous coronary
intervention (PCI) for ST-segment elevation myocardial
infarction (STEMI), but pharmacokinetic principles predict
that the intracoronary (IC) route would be better. Because
of the short half-life of abciximab and its avid binding to
multiple integrin types during the first pass through the
systemic circulation, less drug may reach exposed IIb/IIIa
epitopes on activated platelets within the culprit lesion after
IV bolus than after direct IC administration (1). Supporting
See page 1447
this concept, a small mechanistic study of 16 patients with
STEMI (2) showed that IC abciximab compared with IV
abciximab produced immediately higher IIb/IIIa receptor
occupancy in platelets sampled in coronary sinus blood (94%
vs. 74%). Thirty minutes later, however, no difference in
receptor occupancy was seen (93% vs. 92%). Whether IC
abciximab can reduce infarct size or improve clinical out-
comes has been evaluated in several clinical trials.
IC abciximab versus no abciximab. In the INFUSE-AMI
(Intracoronary Abciximab Infusion and Aspiration Throm-
bectomy in Patients Undergoing Percutaneous Coronary
Intervention for Anterior ST-Segment Elevation Myocar-
dial Infarction) trial, 452 patients within 4 h of STEMI
caused by proximal or mid left anterior descending artery
occlusion undergoing primary PCI were randomized to
bolus IC abciximab delivered locally into the culprit lesion
or to no abciximab (3). The use of bolus IC abciximab
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Florida.
Dr. Bittl has reported that he has no relationships relevant to the contents of this
paper to disclose.compared with no abciximab produced a significant reduc-
tion in the primary endpoint of infarct size at 30 days
(15.1% vs. 17.9% of the left ventricle), as assessed with
cardiac magnetic resonance (CMR) imaging.
IC abciximab versus IV abciximab. Another trial using a
different protocol arrived at a different primary conclusion
(Table 1). In the AIDA STEMI (Abciximab Intracoronary
versus intravenous Drug Application in ST-Elevation Myo-
cardial Infarction) trial (4), 2,065 all comers within 12 h of
STEMI were randomized to bolus IC abciximab (plus IV
infusion) or to bolus IV abciximab (plus IV infusion). The
use of bolus IC abciximab compared with bolus IV abcix-
imab produced no improvement in the primary endpoint of
death, new myocardial infarction (MI), or heart failure at 90
days (7.0% vs. 7.6%), as compared with those randomized to
IV abciximab.
A systematic analysis, embedded in the AIDA-STEMI
report (4), of 8 randomized trials including 3,158 patients,
also reported that the use of IC abciximab compared with
IV abciximab produced no difference in death (risk ratio:
0.9; 95% confidence interval: 0.5 to 1.5) or MI (risk ratio:
0.8; 95% confidence interval: 0.5 to 1.4).
Infarct size after IC versus IV abciximab. A report of a
substudy of the AIDA-STEMI trial, which appears in this
issue of the Journal (5), provides additional information
about the role of IC abciximab. In 795 patients, Eitel et al.
(5) performed CMR within 1 week to compare infarct size
after IC or IV abciximab. The investigators found that the
use of IC abciximab compared with IV abciximab produced
no difference in infarct size (16% vs. 17% of the left
ventricle).
Is infarct size an appropriate endpoint? Recent studies
suggest that infarct size measured by CMR is a stronger
predictor of outcomes after MI than ejection fraction or
other measures of left ventricular function (6). The question
of whether infarct size is an appropriate surrogate for clinical
outcomes can be explored by reviewing the CMR findings
in recent studies. In the AIDA-STEMI substudy (5),
patients with major adverse cardiac events (MACE) had
larger infarcts than those without MACE (24% vs. 16% of
the left ventricle), suggesting that CMR measurements of
infarct size have prognostic value.
In the INFUSE-AMI trial (3), infarct size could not be
correlated with clinical outcomes because only 2 of 31
patients (6.5%) with MACE underwent CMR imaging at
30 days. The primary results of the INFUSE-AMI trial can
be analyzed, however, to determine whether the reduction
in infarct size seen with IC abciximab corresponded to
improved clinical outcomes. Although the observed 16%
reduction in infarct size was less than the 25% reduction
prospectively defined as clinically meaningful (3,5), the
difference in infarct size after IC abciximab compared with
no abciximab reached statistical significance (p  0.03) but
was not associated with a reduction in major adverse cardiac
or cerebrovascular events (4.8% vs. 3.2%) (3), suggesting
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IC or IV Abciximab April 2, 2013:1455–7that CMR measurements in this setting had limited prog-
nostic value. Fortunately, the clinical endpoints in the
INFUSE-AMI trial (3), the AIDA-STEMI trial (4,5), and
several other recent trials (7–10) help to define the role of
abciximab in current practice.
Drug therapy during PCI for STEMI. Refinements in
the use of oral antiplatelet agents (7–9) and bivalirudin (10)
have narrowed the indications for abciximab during PCI for
STEMI. The decision to use abciximab, an inhibitor of
platelet aggregation, can be guided in part by the adequacy
of concurrent therapy with aspirin and P2Y12 receptor
blockers, which are inhibitors of separate pathways for
platelet activation. Stressing the critical role of oral anti-
platelet agents, the 2013 American College of Cardiology
Foundation/American Heart Association guideline (11) rec-
ommends aspirin and P2Y12 receptor blockers for all patients
ndergoing PCI for STEMI, with either unfractionated hep-
rin or bivalirudin (Class of Recommendation I).
Oral aspirin is absorbed rapidly, predominantly from the
pper small intestine, and appreciable concentrations appear
n plasma within 30 min (12). True resistance to aspirin is
ither rare or nonexistent in normal individuals (13), but
elayed or reduced gastrointestinal absorption may lead to a
ondition known as aspirin pseudoresistance (13).
Pre-treatment with clopidogrel probably reduces mortal-
ty in patients with STEMI. It was shown in a meta-analysis
7) that administering clopidogrel before PCI for STEMI
as been associated with a lower incidence of death than
dministering the drug later (1.28% vs. 2.54%, p  0.04).
lopidogrel resistance is well described, but studies have
ow documented that both prasugrel and ticagrelor may
lso have a delayed onset of platelet inhibition during
TEMI (14). Slowed gastrointestinal absorption or an
ntensely thrombotic milieu may retard the onset of platelet
Trial ComparisonsTable 1 Trial Comparisons
INFUSE-AMI Trial
Protocols
Indication Anterior STEMI 4
Adjunctive anticoagulant Bivalirudin
No. 229
Treatment comparison IC abciximab
IC administration Local infusion
IV abciximab infusion No
Outcomes
Primary endpoint Infarct size measured
Main results Positive
Timing of CMR, d 30
No. undergoing CMR 181
Infarct size (% of LV) 15
Timing of death rates, days 30
Death rates, (%) 3.5
*p  0.03.
CMR  cardiac magnetic resonance; HF  heart failure; IC  intracoronary; IV  intravenous;nhibition in this setting (14). The 2013 American Collegef Cardiology Foundation/American Heart Association
uideline (11) now recommends IV abciximab for selected
atients with STEMI receiving unfractionated heparin
Class of Recommendation IIa) and states that IC abcix-
mab may be reasonable in limited circumstances (Class of
ecommendation IIb).
ractical approaches. Abciximab should be used when
spirin and P2Y12 receptor blockers might fail or cannot be
iven before PCI for STEMI. When emesis prevents the
ngestion of oral antiplatelet agents or when cardiogenic
hock, low output, or diabetic gastroparesis impairs gastro-
ntestinal absorption, particularly in treatment-naïve pa-
ients, abciximab may be indicated during PCI for STEMI.
n high-risk situations such as stent thrombosis or extensive
ntracoronary thrombus, IC abciximab may be preferable to
V abciximab. When IC abciximab is selected, a technical
earl is to convert an aspiration-thrombectomy catheter to a
rug-infusion system by disconnecting the suction syringe
nd pushing a bolus of abciximab through the aspiration
orts. Local delivery is preferable to guide-catheter infusion,
hich tends to blow drug back into the aorta or send it
referentially into the lower resistance circuit of nonculprit
oronary arterial branches. In either case, it is reassuring to see
hat local delivery (3) and guide-catheter infusion (4) both
onstitute safe approaches for administering abciximab.
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